Not provided
Not provided
Not provided
Not provided
Not provided
The sponsor terminated the study prior to data analysis for financial reasons.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this research study is to test the safety, tolerability, and effectiveness of corneal collagen cross-linking (CXL), when used to treat keratoconus.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CXL Treatment | Experimental | Eyes randomized to the CXL treatment group with be treated with riboflavin and UV light. |
|
| Sham Control | Active Comparator | Eyes in the control group will be treated with riboflavin only. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| The VEGA UV-A Illumination System | Device | This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in Corneal Curvature. | 6 Months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Barnet Dulaney Perkins Eye Center | Phoenix | Arizona | 85016 | United States | ||
| Woolfson Eye Institute |
Patients that were excluded from the clinical trial were considered screen failures due to not meeting one or more of the inclusion/exclusion criteria.
Patients were recruited from August, 2010 to December 2011 from medical clinics throughout the country.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | CXL Treatment | Eyes randomized to the CXL treatment group with be treated with riboflavin and UV light. |
| FG001 | Sham Control | Eyes in the control group will be treated with riboflavin only. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | CXL Treatment | Eyes randomized to the CXL treatment group with be treated with riboflavin and UV light. |
| BG001 | Sham Control | Eyes in the control group will be treated with riboflavin only. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change in Corneal Curvature. | The CXL-001 study was completed but data analysis was not done. Prior to data analysis, the sponsor, Topcon, decided to terminate the study for administrative reasons only, and not as a result of any safety issues or concerns relating to the study. | Posted | 6 Months |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | CXL Treatment | Eyes randomized to the CXL treatment group with be treated with riboflavin and UV light. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Robert Gibson | Topcon Medical Systems | (201) 599-5121 | RGIBSON@TOPCON.COM |
Not provided
| ID | Term |
|---|---|
| D007640 | Keratoconus |
| ID | Term |
|---|---|
| D003316 | Corneal Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D012256 | Riboflavin |
| ID | Term |
|---|---|
| D005415 | Flavins |
| D011621 | Pteridines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Riboflavin | Drug | Riboflavin is a solution that will be delivered to the treatment area |
|
| Atlanta |
| Georgia |
| 30328 |
| United States |
| Minnesota Eye Consultants | Bloomington | Minnesota | 55431 | United States |
| Pamel Vision & Laser Group | New York | New York | 10021 | United States |
| Mt. Sinai Hospital | New York | New York | 10029 | United States |
| OSU Department of Ophthalmoloty | Columbus | Ohio | 43212 | United States |
| Revision Advanced Laser Eye Center | Columbus | Ohio | 43240 | United States |
| Dell Laser Consultants | Austin | Texas | 78746 | United States |
| Slade & Baker Vision Center | Houston | Texas | 77027 | United States |
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Units | Counts |
|---|
| Participants |
|
| 0 |
| 61 |
| 0 |
| 61 |
| EG001 | Sham Control | Eyes in the control group will be treated with riboflavin only. | 0 | 66 | 0 | 66 |
All such Confidential Information shall remain the property of Topcon, as applicable, and Institution agrees that neither it nor Principal Investigator nor any of its employees or Sub-Investigators, if any, shall disclose any of the Confidential Information to third parties, without the prior written consent of Topcon.
| D006571 | Heterocyclic Compounds |
| D006575 | Heterocyclic Compounds, 3-Ring |
| D003067 | Coenzymes |
| D045762 | Enzymes and Coenzymes |
| D010860 | Pigments, Biological |
| D001685 | Biological Factors |